Limiting the progression of Echocardiographically-assessed left ventricular dysfunction in Diabetes Mellitus (LEAVE-DM) trial

Project Details

The aim of this study was to prevent the progression of heart failure, assessed as the development left ventricular dysfunction on echocardiography, and improve functional capacity assessed by a 6-minute walk test.

Patron ID: PAT047

Lead Organisation:

Baker Institute

Project Lead :

Prof Tom Morwick

Overview:

Heart failure is the most common cardiac complication of type 2 diabetes mellitus. Dapagliflozin is a medication that is commonly used in the treatment of diabetes. It has been shown to have good cardiovascular benefits, particularly in people with advanced heart failure.

This project aims to discover if dapagliflozin can reduce the development of heart failure in people from the community with type 2 diabetes at risk of developing the condition.  The Patron data will be used to search for a cohort of type 2 diabetes patients aged over 65 years and invite them to participate in the trial.